STOCK TITAN

C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

WATERTOWN, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 2:50 p.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.    


FAQ

What is the date and time of C4 Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

C4 Therapeutics will present on January 14, 2021, at 2:50 p.m. ET.

How can I access the live webcast of C4 Therapeutics' presentation?

The live webcast can be accessed under the 'Events & Presentations' section on C4 Therapeutics' website.

How long will the replay of the webcast be available after C4 Therapeutics' presentation?

The replay of the webcast will be available for at least two weeks following the presentation.

What is the focus of C4 Therapeutics' biopharmaceutical approach?

C4 Therapeutics focuses on developing therapeutic candidates that selectively destroy disease-causing proteins to treat cancer and neurodegenerative diseases.

What advantages does C4 Therapeutics claim over traditional therapies?

C4 Therapeutics claims advantages such as the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects.
C4 Therapeutics, Inc.

NASDAQ:CCCC

CCCC Rankings

CCCC Latest News

CCCC Stock Data

88.74M
57.87M
11.51%
91.51%
12.04%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WATERTOWN